Catalyst Pharmaceuticals Reports Strong Third Quarter 2024 Financial Results and Provides Corporate Update
November 06, 2024 16:12 ET
|
Catalyst Pharmaceuticals, Inc.
Reports Q3 2024 Total Revenues of $128.7 Million, Representing a 25.3% YoY Increase Record Revenues Driven by Continued Organic Growth in its Rare Disease Franchise Robust Financial Performance...
Catalyst Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 6, 2024
October 22, 2024 08:03 ET
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...
Angelini Pharma stipula un accordo di opzione di licenza esclusiva con Cureverse per lo sviluppo e la commercializzazione a livello mondiale di una nuova e innovativa sostanza per la salute del cervello in fase clinica
October 21, 2024 00:00 ET
|
Angelini Pharma
L'accordo conferisce ad Angelini Pharma un'opzione di licenza esclusiva per lo sviluppo e la commercializzazione di CV-01, un nuovo composto in fase clinica 1 con un grande potenziale per il...
Angelini Pharma Enters Into An Exclusive Option Agreement With Cureverse to License Global Development and Commercialization Rights For A Novel and Innovative Clinical-Stage Brain Health Asset
October 21, 2024 00:00 ET
|
Angelini Pharma
Angelini Pharma Enters Into Exclusive Option Agreement With Cureverse to License Global Development & Commercialization Rights
For Brain Health Asset
Epilepsy Foundation Welcomes New Chief Financial Officer
October 16, 2024 12:05 ET
|
Epilepsy Foundation
The Epilepsy Foundation announced today the appointment of Wanda Cook as the new chief financial officer.
Catalyst Pharmaceuticals Donates $100,000 to the American Red Cross Hurricane Helene Relief Efforts
October 08, 2024 08:03 ET
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "the Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on...
Catalyst Pharmaceuticals to Participate in the BofA Securities CNS Therapeutics Virtual Conference 2024
October 01, 2024 08:03 ET
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...
Epilepsy Foundation Awards $200,000 at 12th Annual Shark Tank Competition
September 30, 2024 08:00 ET
|
Epilepsy Foundation
Epilepsy Foundation announced today it has awarded $200,000 in funding for two startups who competed in the Foundation’s 2024 Shark Tank Competition.
Neurona Therapeutics Announces Participation in Upcoming Investor Conferences in October
September 27, 2024 14:00 ET
|
Neurona Therapeutics
Neurona Therapeutics Announces Participation in Upcoming Investor Conferences in October
Crossject annonce son éligibilité au dispositif d’investissement PEA-PME
September 26, 2024 01:30 ET
|
CROSSJECT
Le PEA-PME permet aux investisseurs particuliers français d'acheter des titres à des conditions fiscales préférentielles. Dijon, Sept 26, 2024 -- Crossject (ISIN : FR0011716265 ; Euronext : ALCJ),...